ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$30.04
+1.04% today
Updated 2026-06-12
Market cap
$21.57B
P/E ratio
—
P/S ratio
2,611.49x
EPS (TTM)
$-0.54
Dividend yield
—
52W range
$11 – $33
Volume
5.6M
Roivant Sciences Ltd (ROIV) Insider transactions
Net insider activity
Net selling (18,307,497 shares)
Buy transactions
23
Sell transactions
77
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-05-22 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $30.27 | $6.05M |
| 2026-05-20 | VENKER, ERIC | President & Immunovant CEO | Sale | 34,483 | $32.41 | $1.12M |
| 2026-05-20 | PULIK, RICHARD | CFO | Sale | 18,962 | $32.41 | $614558.42 |
| 2026-04-20 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-04-20 | VENKER, ERIC | President & Immunovant CEO | Buy | 200,000 | $3.85 | $770000.00 |
| 2026-04-20 | PULIK, RICHARD | CFO | Buy | 84,026 | — | — |
| 2026-04-20 | PULIK, RICHARD | CFO | Buy | 60,644 | — | — |
| 2026-04-20 | HUMES, JENNIFER | Chief Accounting Officer | Buy | 27,157 | — | — |
| 2026-04-20 | HUMES, JENNIFER | Chief Accounting Officer | Buy | 29,173 | — | — |
| 2026-04-17 | OREN, ILAN | Director | Buy | 896 | — | — |
| 2026-04-17 | OREN, ILAN | Director | Sale | 95 | $29.83 | $2833.85 |
| 2026-04-17 | MOMTAZEE, JAMES C | Director | Buy | 469 | — | — |
| 2026-04-17 | MOMTAZEE, JAMES C | Director | Sale | 94 | $29.83 | $2804.02 |
| 2026-04-17 | EPPERLY, MELISSA B, | Director | Buy | 670 | — | — |
| 2026-04-16 | GLINE, MATTHEW | Director, CEO | Sale | 289,774 | $29.16 | $8.45M |
| 2026-04-08 | HUMES, JENNIFER | Chief Accounting Officer | Sale | 13,538 | $28.37 | $384073.06 |
| 2026-03-31 | TORTI, FRANK | President and Vant Chair | Sale | 160,035 | $27.70 | $4.43M |
| 2026-03-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 187,512 | $27.70 | $5.19M |
| 2026-03-31 | GLINE, MATTHEW | Director, CEO | Sale | 304,684 | $27.70 | $8.44M |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 58,391 | — | — |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 29,809 | $26.41 | $787255.69 |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,306,889 | $11.50 | $15.03M |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Buy | 97,319 | — | — |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Sale | 53,826 | $26.41 | $1.42M |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Sale | 2,178,150 | $11.50 | $25.05M |
| 2026-03-26 | FITZGERALD, MEGHAN | Director | Sale | 70,000 | — | — |
| 2026-03-26 | FITZGERALD, MEGHAN | Director | Buy | 70,000 | $8.80 | $616000.00 |
| 2026-03-20 | PULIK, RICHARD | CFO | Sale | 1,546 | $27.70 | $42824.20 |
| 2026-03-20 | HUMES, JENNIFER | Chief Accounting Officer | Sale | 14,526 | $27.70 | $402370.20 |
| 2026-03-17 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-03-17 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $28.24 | $5.65M |
| 2026-03-16 | EPPERLY, MELISSA B, | Director | Sale | 41,861 | $28.68 | $1.20M |
| 2026-02-23 | TORTI, FRANK | President and Vant Chair | Sale | 587,390 | — | — |
| 2026-02-23 | TORTI, FRANK | President and Vant Chair | Sale | 587,390 | $27.51 | $16.16M |
| 2026-02-20 | VENKER, ERIC | President & Immunovant CEO | Sale | 7,051 | $27.15 | $191434.65 |
| 2026-02-20 | TORTI, FRANK | President and Vant Chair | Sale | 1,012,610 | — | — |
| 2026-02-20 | TORTI, FRANK | President and Vant Chair | Sale | 1,012,610 | $27.15 | $27.49M |
| 2026-02-20 | PULIK, RICHARD | CFO | Sale | 1,000 | $27.15 | $27150.00 |
| 2026-02-19 | TORTI, FRANK | President and Vant Chair | Sale | 1,400,000 | — | — |
| 2026-02-19 | TORTI, FRANK | President and Vant Chair | Buy | 1,400,000 | $3.85 | $5.39M |
| 2026-02-13 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-02-13 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $26.49 | $5.30M |
| 2026-02-13 | QVT, FINANCIAL LP | Director by Deputization | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | QVT, FINANCIAL LP | Director by Deputization | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-13 | MANCHESTER, KEITH S | Director | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | MANCHESTER, KEITH S | Director | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-13 | GOLD, DANIEL ALLEN | Director | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | GOLD, DANIEL ALLEN | Director | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-12 | QVT, FINANCIAL LP | Director by Deputization | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | QVT, FINANCIAL LP | Director by Deputization | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-12 | MANCHESTER, KEITH S | Director | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | MANCHESTER, KEITH S | Director | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-12 | GOLD, DANIEL ALLEN | Director | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | GOLD, DANIEL ALLEN | Director | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-11 | QVT, FINANCIAL LP | Director by Deputization | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-11 | MANCHESTER, KEITH S | Director | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-11 | GOLD, DANIEL ALLEN | Director | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 651,558 | — | — |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 651,558 | $12.68 | $8.26M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 339,441 | $26.47 | $8.99M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 312,117 | $26.47 | $8.26M |
| 2026-01-20 | OREN, ILAN | Director | Buy | 1,164 | — | — |
| 2026-01-20 | OREN, ILAN | Director | Sale | 124 | $22.98 | $2849.52 |
| 2026-01-20 | MOMTAZEE, JAMES C | Director | Buy | 609 | — | — |
| 2026-01-20 | MOMTAZEE, JAMES C | Director | Sale | 122 | $22.98 | $2803.56 |
| 2026-01-20 | EPPERLY, MELISSA B, | Director | Buy | 815 | — | — |
| 2026-01-20 | EPPERLY, MELISSA B, | Director | Sale | 54 | $22.98 | $1240.92 |
| 2026-01-12 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-01-12 | VENKER, ERIC | President & Immunovant CEO | Buy | 200,000 | $3.85 | $770000.00 |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 2,449,877 | — | — |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 2,449,877 | $12.68 | $31.06M |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,430,882 | $21.71 | $31.06M |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,018,995 | $21.71 | $22.12M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 748,358 | — | — |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 748,358 | $12.68 | $9.49M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 436,485 | $21.74 | $9.49M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 311,873 | $21.74 | $6.78M |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Sale | 117,848 | — | — |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Buy | 117,848 | $3.85 | $453714.80 |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Sale | 75,000 | $22.53 | $1.69M |
| 2025-12-24 | TORTI, FRANK | President and Vant Chair | Sale | 110,489 | — | — |
| 2025-12-24 | TORTI, FRANK | President and Vant Chair | Sale | 64,891 | $22.47 | $1.46M |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Sale | 313,841 | — | — |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Buy | 313,841 | $3.85 | $1.21M |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $22.45 | $4.49M |
| 2025-12-23 | TORTI, FRANK | President and Vant Chair | Buy | 175,380 | $22.45 | $3.94M |
| 2025-12-23 | PULIK, RICHARD | CFO | Sale | 260,000 | — | — |
| 2025-12-23 | PULIK, RICHARD | CFO | Buy | 260,000 | $3.85 | $1.00M |
| 2025-12-23 | PULIK, RICHARD | CFO | Sale | 146,731 | $22.39 | $3.29M |
| 2025-12-20 | PULIK, RICHARD | CFO | Sale | 2,129 | $22.41 | $47710.89 |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 59,513 | — | — |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 32,682 | $23.09 | $754627.38 |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 26,831 | $23.09 | $619527.79 |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 432,718 | $23.05 | $9.97M |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 189,538 | $23.17 | $4.39M |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 155,076 | $23.02 | $3.57M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 432,718 | $23.05 | $9.97M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 189,538 | $23.17 | $4.39M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 155,076 | $23.02 | $3.57M |
Frequently asked questions
Are ROIV insiders buying or selling?
Over the transactions on record, ROIV insiders have been net sellers, with about $366.34M in stock sold across 77 sales, against 11 open-market purchases.
Does insider selling at ROIV mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which ROIV insiders are selling the most?
Recent selling is concentrated in a few names. SUKHATME, MAYUKH accounts for the largest share on record, with about $109.09M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.